The Most Recommended Site for Subcutaneous Remodulin® (Treprostinil) Pump to Minimize Patient Pain | ||||
| Cardiovascular Research Prove Journal | ||||
| Volume 8, Issue 2, December 2024 PDF (1.23 MB) | ||||
| Document Type: Abstracts | ||||
| DOI: 10.21608/cvrepj.2024.400099 | ||||
 View on SCiNiTO | ||||
| Abstract | ||||
| The first Remodulin® I-jet pump implantation in Egypt was performed in 2017 at the Magdy Yacoub Aswan Heart Centre. Face flushing, headaches, jaw pain, cramping, diarrhea, and pain at the insertion site are major side effects of the drug. According to clinical studies, site pain reaches up to 93% of patients with Remodulin® pump. Some patients at Aswan Heart Center want to discontinue the treatment because of the intense pain | ||||
|
Statistics Article View: 122 PDF Download: 73 |
||||
